<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5106">
  <stage>Registered</stage>
  <submitdate>12/07/2015</submitdate>
  <approvaldate>12/07/2015</approvaldate>
  <nctid>NCT02514512</nctid>
  <trial_identification>
    <studytitle>Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking</studytitle>
    <scientifictitle>Phase I Feasibility Study of Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation and Radiofrequency Tracking</scientifictitle>
    <utrn />
    <trialacronym>LIGHTSABR</trialacronym>
    <secondaryid>HREC/15/HAWKE/55</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neoplasms</healthcondition>
    <healthcondition>Lung Neoplasms</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - MLC Tracking

No Intervention: Standard SABR - Patients receive standard treatment

Experimental: MLC Tracking SABR - Patients are treated with MLC tracking


Treatment: devices: MLC Tracking
Treat patient with Non FDA approved MLC Tracking

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Feasibility - Percentage of fractions delivered without software or mechanical failure</outcome>
      <timepoint>Assessed at 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Audio Visual (AV) Biofeedback - Fraction of patients for whom AV biofeedback improves breathing regularity</outcome>
      <timepoint>Assessed at 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Coefficient of variation in breathing patterns - Breathing variations over imaging and treatment sessions with and without AV biofeedback using a statistical process for coefficient of variation</outcome>
      <timepoint>Assessed at 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target volumes - Target volumes between the 4 Dimensional (4D) planning MLC tracking and Internal Target Volume (ITV) (standard) planning</outcome>
      <timepoint>Assessed at 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lung dose - Difference in dose to healthy lung in treatment plans between 4D planning and ITV planning</outcome>
      <timepoint>Assessed at 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treated dose - MLC tracking - Difference between the treated dose and planned dose for MLC tracking</outcome>
      <timepoint>Assessed at 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treated dose - standard - Difference between the estimated treated dose and planned dose for ITV treatments</outcome>
      <timepoint>Assessed at 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4D Cone Beam CT (CBCT) image quality - Image quality and target position differences between the Calypso-based 4D CBCT image reconstruction and Revs Per Minute (RPM)-based 4D CBCT image reconstruction using Feldkamp filtered backprojection (FDK and iterative reconstruction algorithms.</outcome>
      <timepoint>Assessed at 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Breathing variations with and without continuous positive air pressure (CPAP) - To quantify the breathing variations over treatment sessions with and without application of continuous positive air pressure (CPAP)</outcome>
      <timepoint>At time of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Aged 18 or older

          -  Has provided written Informed Consent for participation in this trial and is willing
             to comply with the study

          -  Patients undergoing external beam radiotherapy at Northern Sydney Cancer Centre

          -  Histologically proven Stage I Non Small Cell Lung Cancer (NSCLC) oligometastatic lung
             metastases (3 or less). Histological diagnosis will be obtained if clinically
             indicated.

          -  MRI/4D-CT prior to insertion of Calypso beacons

          -  Patient must be able to have Varian Calypso beacons placed in the lung (if on
             anticoagulants, must be cleared by Local Medical Officer (LMO) or cardiologist).

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Body habitus enabling Calypso tracking (as per Calypso Determining a Patient's
             Localisation Designation &amp; Orientation before implantation)

          -  A maximum of three metastases to the lung from any non-haematological malignancy.
             Multiple metastases will be treated separately.

          -  Tumour diameter = = 5cm</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous high-dose thoracic radiotherapy.

          -  Less than two Calypso beacons implanted in the lung.

          -  Calypso beacons are spaced by greater than 9cm or less than 1cm.

          -  Calypso beacons are less than 19cm from outer chest wall

          -  Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently
             with treatment. Hormonal manipulation agents are allowable (e.g. aromatase inhibitors,
             selective oestrogen receptor modulators, and gonadotropin releasing hormone receptor
             modulators)

          -  Targeted agents (such as sunitinib, bevacizumab and tarceva) within 7 days of
             commencement of treatment, or concurrently with treatment

          -  Women who are pregnant or lactating.

          -  Unwilling or unable to give informed consent

          -  Unwilling or unable to complete quality of life questionnaires</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <postcode>2112 - St Leonards</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Royal North Shore Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Sydney</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Varian Medical Systems</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A research study into a new technology for adjustment of the radiotherapy beam to account for
      movement of lung tumours as the patient breathes during radiotherapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02514512</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Thomas Eade, MD</name>
      <address>RNSH</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Clare Banks, MPH</name>
      <address />
      <phone>61 2 9463 1345</phone>
      <fax />
      <email>clare.banks@health.nsw.gov.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>